Conclusions

PBPK model of pravastatin, based on in vitro transport parameters and scaling factors, was developed. The approach described can be used to predict the pharmacokinetics and DDIs associated with hepatic uptake transporters.

Notes

ACKNOWLEDGMENTS & DISCLOSURES

The authors would like to thank Emi Kimoto and Yi-An Bi for conducting the SCHH studies, and Larry Tremaine and Dennis Scott for the valuable suggestions on the manuscript. All authors are full-time employees of Pfizer Inc.